1 suspended. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Suspended 1 |
Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD - Relapsing Forms of Multiple Sclerosis | Phase 2 | Suspended | Emerald Health Pharmaceuticals | 50 | 2021-10-19 | 2022-10-21 |
Autoimmune Diseases of the Nervous System (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Nervous System Diseases (1)
Autoimmune Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1)
Emerald Health Pharmaceuticals (1)
Australia (1) · United States (1)